Oral nirmatrelvir-ritonavir for COVID-19 in higher risk outpatients
Richards et al., New England Journal of Medicine, PANORAMIC, Sep 2025
PANORAMIC shows that paxlovid did not reduce hospitalization or death, adjusted OR 1.18, 95% Bayesian credible interval [0.55-2.62].
Ony minimal results are currently available in the abstract for a hidden paper.
Standard of Care (SOC) for COVID-19 in the study country,
the United Kingdom, is
very poor with
very low average efficacy for approved treatments
1.
The United Kingdom focused on expensive high-profit treatments, approving only one low-cost early treatment, which required a prescription and had limited adoption. The high-cost prescription treatment strategy reduces the probability of early treatment due to access and cost barriers, and eliminates complementary and synergistic benefits seen with many low-cost treatments.
|
risk of death/hospitalization, 17.9% higher, RR 1.18, p = 0.69, treatment 14 of 1,698 (0.8%), control 11 of 1,673 (0.7%), odds ratio converted to relative risk, day 28.
|
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Richards et al., 12 Sep 2025, Randomized Controlled Trial, United Kingdom, peer-reviewed, 1 author, study period 12 April, 2022 - 28 March, 2024, PANORAMIC trial.
